<- Go Home
4basebio PLC
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and sale of synthetic DNA and RNA products in Europe, the United States, and internationally. It offers hpDNA, a double stranded linear DNA for viral and non-viral vector applications; opDNA, a partially opened, linear, double stranded DNA for in vitro transcription processes that produce mRNA for use in vaccines and therapeutics; oeDNA, a linear, double stranded DNA for genome editing; osDNA, a DNA product that incorporates nucleotide modifications within the DNA backbone; and Hermes, a nanoparticle platform. The company also provides custom pegRNA and sgRNA manufacturing; and nanoparticle formulation services. Its products are used in mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines, and non-viral delivery applications. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is headquartered in Cambridge, the United Kingdom.
Market Cap
GBP 81.6M
Volume
1.1K
Cash and Equivalents
GBP 17.8M
EBITDA
-GBP 15.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
GBP 974.0K
Profit Margin
57.53%
52 Week High
GBP 10.00
52 Week Low
GBP 4.20
Dividend
N/A
Price / Book Value
8.07
Price / Earnings
-4.82
Price / Tangible Book Value
10.81
Enterprise Value
GBP 80.3M
Enterprise Value / EBITDA
-5.13
Operating Income
-GBP 16.7M
Return on Equity
92.65%
Return on Assets
-28.04
Cash and Short Term Investments
GBP 18.0M
Debt
GBP 16.7M
Equity
GBP 10.1M
Revenue
GBP 1.7M
Unlevered FCF
-GBP 11.6M
Sector
Biotechnology
Category
N/A